The Department of Energy (DOE)’s National Nuclear Security Administration has issued a fourth, and final, cooperative agreement to Corvallis, Oregon-based Northwest Medical Isotopes, LLC for the production of molybdenum-99 (Mo-99).
In July, the DOE awarded cooperative agreements to three other U.S. companies: Niowave, Inc., located in Lansing, Michigan; NorthStar Medical Radioisotopes, LLC, located in Beloit, Wisconsin; and SHINE Medical Technologies, located in Janesville, Wisconsin.
All four companies will receive $15 million in funding, and requires the awardees provide a $15 million match. The ultimate goal of these agreements, part of the larger American Medical Isotopes Production Act of 2012, is to establish a reliable domestic supply of Mo-99.
“Mo-99 is a critical medical isotope that empowers us to fight back against heart disease and cancer,” said Lisa E. Gordon-Hagerty, DOE undersecretary for nuclear security and NNSA administrator, in a statement. “These agreements will facilitate its domestic production without highly enriched uranium, greatly reducing the potential for proliferation of nuclear materials.”